Agilent Technologies, Inc. (BIT:1A)
Italy
· Delayed Price · Currency is EUR | Market Cap | 27.85B |
| Revenue (ttm) | 5.95B |
| Net Income (ttm) | 1.09B |
| Shares Out | n/a |
| EPS (ttm) | 3.81 |
| PE Ratio | 25.65 |
| Forward PE | 18.80 |
| Dividend | 0.45 (0.45%) |
| Ex-Dividend Date | Jan 5, 2026 |
| Volume | n/a |
| Average Volume | 23 |
| Open | n/a |
| Previous Close | 98.38 |
| Day's Range | n/a |
| 52-Week Range | 75.66 - 137.72 |
| Beta | n/a |
| RSI | 46.17 |
| Earnings Date | May 26, 2026 |
About Agilent Technologies
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnosti... [Read more]
Financial Performance
In fiscal year 2025, Agilent Technologies's revenue was $6.95 billion, an increase of 6.73% compared to the previous year's $6.51 billion. Earnings were $1.30 billion, an increase of 1.09%.
Financial numbers in USDNews
Axion BioSystems and Agilent Technologies Resolve Litigation
ATLANTA--(BUSINESS WIRE)--Axion BioSystems, Inc., a leading provider of live-cell analysis technologies, today announced that Agilent Technologies, Inc. and Axion BioSystems have fully resolved the is...
Agilent Showcases Cancer Research Solutions at AACR 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics ...
Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfo...
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, ...
Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United S...
Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development an...
Agilent to acquire Biocare Medical in $950 million all-cash deal
Life sciences firm Agilent Technologies said on Monday that it will acquire clinical pathology firm Biocare Medical in an all-cash deal valued at $950 million.
Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies
Denver, CO and London, UK, 9 March 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, GHO Capital Partners L...
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire ...
Agilent Technologies Transcript: TD Cowen 46th Annual Health Care Conference
Management reported strong growth in key markets, driven by innovation and favorable industry trends. Guidance for the year remains intact, with disciplined capital allocation and ongoing investments in digital, AI, and capacity expansion. Margin expansion and free cash flow are on track, supported by robust demand and prudent risk management.
Agilent reports in-line first quarter, says results hurt by US snowstorm
Life sciences firm Agilent Technologies on Wednesday reported first-quarter results that were largely in line with Wall Street estimates on stable demand for its medical tools and equipment used in la...
Agilent Technologies Earnings Call Transcript: Q1 2026
Q1 2026 saw 4.4% core revenue growth to $1.8B, with strong performance in pharma, CAM, and diagnostics, despite a $10M weather impact. FY 2026 guidance is maintained at 4%-6% core growth and EPS of $5.90-$6.04, with margin expansion expected as tariff headwinds ease.
Agilent Reports First-Quarter Fiscal Year 2026 Financial Results
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #CustomerFirst--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth ...
Agilent to Participate in TD Cowen's 46th Annual Health Care Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas...
Agilent Announces Cash Dividend of 25.5 Cents per Share
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22,...
Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award
SANTA CLARA, Calif.--(BUSINESS WIRE)-- #CircularEconomy--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent's inaugural Instrument...
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 p...
Agilent Showcases Next‑Generation Automated Solutions at SLAS2026
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) announced today that it will present a range of next‑generation automated workflow innovations...
Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2026 after the stock marke...
Agilent Accelerates Digital Pathology with the Launch of the Agilent S540MD Slide Scanner System
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (...
Agilent Technologies Transcript: 44th Annual J.P. Morgan Healthcare Conference
Management outlined a strategy centered on customer-centric innovation, digital transformation, and operational efficiency through the Ignite system. FY26 guidance projects 4%-6% core revenue growth, margin expansion, and strong momentum in pharma, CDMO, and digital channels.
Agilent to Present at the 44th Annual J.P. Morgan Healthcare Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #BringGreatScienceToLife--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annua...
Agilent Technologies Transcript: Citi Annual Global Healthcare Conference 2025
The conference highlighted a shift to enterprise-wide transformation, regionalized operations, and AI-driven customer support. Financial guidance for 2026 projects 4–6% growth, with stable China revenue and mid-teens CDMO growth. Reshoring and M&A integration are key long-term priorities.
Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc (NYSE: A) today announced the release of a new 21 CFR Part 11 compliance software for the Agilent xCELLigence Real-Time Cell Analysis (RT...